SIBO vs. IBS vs. IMO vs. SIFO vs. Dysbiosis: A Diagnostic Decision Tree

If you have been dealing with chronic bloating, irregular bowel habits, or abdominal pain, you have probably encountered a confusing set of abbreviations. SIBO. IBS. IMO. SIFO. Dysbiosis. These terms get used interchangeably on social media, sometimes by practitioners who should know better, and the result is a fog of overlapping labels that makes it hard to know what you actually have or what to do about it. The problem is real: these conditions share symptoms, they can coexist in the same person, and the diagnostic tools we have are imperfect. But they are not the same thing, and treating one when you have another can mean months of wasted time and money. This article lays out what each condition actually is, how they are diagnosed, where they overlap, and how to think about the diagnostic process in a way that is actually useful.

What each of these conditions actually means

Before building a decision tree, you need clear definitions. The confusion starts because these five terms operate at different levels. Some are clinical diagnoses with established criteria. Others are microbiological findings. And at least one is really more of a concept than a diagnosable condition.

IBS, or irritable bowel syndrome, is a functional gastrointestinal disorder defined by the Rome IV criteria. To meet the definition, you need recurrent abdominal pain averaging at least one day per week in the last three months, associated with two or more of the following: related to defecation, associated with a change in stool frequency, or associated with a change in stool form (Lacy et al., 2016). IBS is subtyped by predominant stool pattern: IBS-D (diarrhea-predominant), IBS-C (constipation-predominant), IBS-M (mixed), and IBS-U (unsubtyped). Critically, IBS is a diagnosis of positive identification based on symptoms, not a diagnosis of exclusion, although most clinicians still rule out other conditions first.

SIBO, or small intestinal bacterial overgrowth, refers to an excessive number of bacteria in the small intestine. The small bowel normally contains relatively few bacteria compared to the colon, maintained by gastric acid, bile, the migrating motor complex, and the ileocecal valve. When these defense mechanisms fail, colonic-type bacteria can proliferate in the small intestine, fermenting carbohydrates and producing gas, bloating, diarrhea, and sometimes malabsorption. The gold standard diagnostic criterion is a jejunal aspirate showing more than 10^3 colony-forming units per milliliter, though some older literature used 10^5 (Rezaie et al., 2017).

IMO, or intestinal methanogen overgrowth, was previously called methane-dominant SIBO, but the name was changed for good reason. The organisms responsible for methane production, primarily Methanobrevibacter smithii, are archaea, not bacteria. And the overgrowth is not limited to the small intestine. It can and does occur in the large bowel. The clinical picture of IMO tends toward constipation rather than diarrhea, because methane directly slows intestinal transit (Pimentel et al., 2020). On a breath test, IMO is identified by elevated methane levels, typically 10 parts per million or above at any point during the test.

SIFO, or small intestinal fungal overgrowth, involves excessive fungal colonization of the small intestine, most commonly Candida species. Erdogan and colleagues at Indiana University identified SIFO via duodenal aspirate culture in approximately 25% of patients presenting with unexplained GI symptoms including bloating, nausea, and diarrhea (Erdogan et al., 2015). SIFO does not have a breath test, and the diagnosis requires endoscopic aspiration, which limits how often it is actually identified.

Dysbiosis is the term that causes the most confusion. It broadly refers to an imbalance in the composition or function of the gut microbial community. The problem is that there is no standardized definition, no universally accepted diagnostic test, and no established threshold for what constitutes 'imbalanced' versus 'normal.' Stool microbiome tests sold directly to consumers often report dysbiosis scores, but these lack clinical validation and cannot reliably guide treatment (Shanahan et al., 2021). Dysbiosis is a research concept that has been prematurely commercialized.

Why the SIBO-in-IBS prevalence ranges from 4 to 78 percent

If you have looked into SIBO, you have probably seen wildly different claims about how common it is among people with IBS. Some sources say the majority of IBS patients actually have SIBO. Others say the overlap is minimal. Both positions cite published research, which seems impossible until you understand what is driving the variation.

The biggest factor is the diagnostic test used. Lactulose breath tests tend to produce higher positivity rates because lactulose is a non-absorbable sugar that reaches the colon in everyone, meaning the test often picks up colonic fermentation and misattributes it to the small intestine. Glucose breath tests have higher specificity because glucose is absorbed in the proximal small bowel, but they miss distal small bowel overgrowth entirely. Jejunal aspirate culture is the gold standard but is invasive, expensive, and not standardized across laboratories. A 2020 meta-analysis by Shah and colleagues found that the choice of test alone could account for most of the variance in reported SIBO prevalence among IBS patients (Shah et al., 2020).

The second factor is the diagnostic cutoff. Even within breath testing, different labs use different thresholds for what constitutes a positive result. The 2017 North American Consensus defined a positive hydrogen breath test as a rise of 20 or more parts per million above baseline within 90 minutes for glucose and within 90 minutes for lactulose (Rezaie et al., 2017). But older studies used different thresholds, different timing windows, and sometimes different baseline definitions. Change the cutoff by five parts per million and your prevalence estimate can shift dramatically.

The third factor is patient selection. Studies recruiting from tertiary referral centers with refractory IBS patients will find higher SIBO rates than studies sampling from primary care populations with milder symptoms. Publication bias adds another layer: studies finding high overlap are more likely to be published because they are more interesting.

A practical diagnostic decision tree

Rather than trying to match yourself to one of these labels based on symptoms alone, a more useful approach follows a branching logic that moves from broad to specific. This is not a replacement for clinical judgment, but it reflects the reasoning that an informed gastroenterologist might use.

Where these conditions overlap and coexist

One of the most important things to understand is that these conditions are not mutually exclusive. A patient can have IBS and SIBO. A patient can have SIBO and SIFO simultaneously. IMO frequently coexists with hydrogen-producing SIBO. And all of these can occur in the context of broader dysbiotic changes in the microbiome.

Erdogan and colleagues found that among patients with culture-confirmed SIFO, a significant proportion also had positive bacterial cultures from the same aspirate, suggesting concurrent SIBO (Erdogan et al., 2015). In clinical practice, this means that treating one condition and seeing only partial improvement does not mean the treatment failed. It may mean there is a second, untreated problem layered on top.

The relationship between motility disorders and microbial overgrowth is particularly important. Conditions that impair the migrating motor complex, including diabetes, hypothyroidism, scleroderma, opioid use, and post-surgical changes, predispose to both SIBO and SIFO because the sweeping action that clears the small bowel between meals is compromised. When the underlying motility issue is not addressed, overgrowth tends to recur even after successful antibiotic treatment (Quigley, 2019).

The dysbiosis problem: why this term creates more confusion than clarity

Dysbiosis deserves special attention because it is the term most likely to be misused by both practitioners and direct-to-consumer testing companies. In research, dysbiosis is a useful shorthand for describing microbial community shifts associated with disease states. Reduced Bacteroidetes, increased Proteobacteria, or decreased short-chain fatty acid production have all been described in various conditions. But these are population-level associations, not individual-level diagnostic criteria.

The problem with consumer microbiome tests that report dysbiosis scores is threefold. First, the reference ranges for 'normal' gut microbiome composition are not well established, because healthy individuals vary enormously in their microbial profiles (Human Microbiome Project Consortium, 2012). Second, stool composition does not reliably reflect small intestinal or mucosal-associated microbial communities. Third, and most critically, no study has demonstrated that acting on a dysbiosis score from a consumer test improves clinical outcomes. A 2021 review in Nature Reviews Gastroenterology and Hepatology concluded that microbiome testing is not ready for routine clinical use outside of specific pathogen detection (Shanahan et al., 2021).

What helps with navigating this diagnostic process

The most practically useful thing you can do before and during the diagnostic process is maintain detailed records of your symptoms, their timing, dietary associations, and bowel patterns. This matters because the decision tree above relies heavily on symptom patterns, and your clinician needs accurate data to navigate it. Tracking tools like GLP1Gut can organize this information so you arrive at appointments with clear patterns rather than vague impressions.

Beyond tracking, a few practical steps can make the diagnostic process less frustrating. First, get celiac disease ruled out with serology before pursuing breath testing, because celiac can mimic every one of these conditions and has a specific, effective treatment. Second, if you are going to do a breath test, follow the preparation protocol carefully, because dietary preparation errors are one of the most common causes of inaccurate results. Third, if your first-line treatment does not work, go back to the diagnostic question rather than assuming the diagnosis was right and the treatment just was not strong enough.

Moving forward when the labels do not fit neatly

The reality of clinical gastroenterology is that many patients do not fit cleanly into one diagnostic box. You may have IBS symptoms with a borderline-positive breath test and some features that suggest SIFO. Your clinician may reasonably try an empiric course of rifaximin and reassess. If that partially helps, the next step might be antifungal treatment or dietary modification. This iterative approach is not a sign of incompetence. It reflects the genuine complexity of overlapping conditions with imperfect diagnostic tools.

What matters most is working with a clinician who understands the distinctions between these conditions, acknowledges the limitations of current testing, and does not anchor prematurely on a single diagnosis. The decision tree is a guide, not a flowchart that produces a definitive answer at the bottom. Used well, it narrows possibilities and directs testing and treatment in a logical sequence. Used poorly, it becomes another way to slap a label on complex symptoms and sell a protocol.